# Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma

> **NCT02113436** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 300 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** FP/ SLM HFA MDI 50/25 mcg
- **DRUG:** FP HFA MDI 50 mcg

## Key facts

- **NCT ID:** NCT02113436
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-01
- **Primary completion:** 2016-06-01
- **Final completion:** 2016-10-01
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2017-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02113436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02113436, "Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT02113436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*